Sort   by:  
 Page size 
UnknownAn intragenic methylated region in the imprinted Igf2 gene augments transcription.
Not available
S-EPMC1084166 | biostudies-literature
UnknownPharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system.
Not available
S-EPMC12165970 | biostudies-literature
UnknownPertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.
Not available
S-EPMC9813086 | biostudies-literature
UnknownIncidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Not available
S-EPMC5834072 | biostudies-literature
UnknownDevelopment of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Not available
S-EPMC7027517 | biostudies-literature
UnknownheredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Not available
S-EPMC11127459 | biostudies-literature
UnknownPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Not available
S-EPMC5584549 | biostudies-literature
Sort   by:  
 Page size